Yin Yeshi, Zhao Changhui, Xiang Qin, Li Zongyan, Liu Xiu, Hu Changhui, Yu Rong
Guangxi Key Laboratory of Animal Reproduction, Breeding and Disease Control, Guangxi Zhuang Autonomous Region Engineering Research Center of Veterinary Biologics, College of Animal Science and Technology, Guangxi University, Nanning, China.
Key Laboratory of Comprehensive Utilization of Advantage Plants Resources in Hunan South, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, China.
Front Pharmacol. 2025 Jun 11;16:1573514. doi: 10.3389/fphar.2025.1573514. eCollection 2025.
Animal and cell studies have demonstrated that Zuogui-Jiangtang-Yishen decoction (ZGJTYS) has a favorable effect on the treatment of diabetic kidney disease (DKD). Our previous clinical research also showed that ZGJTYS prevents DKD in a manner similar to that of benazepril. Nevertheless, the interactions between ZGJTYS and the human gut microbiota require further investigation, particularly its interference in the intestinal flora response to food ingredients that may increase DKD risk, such as L-α-phosphatidylcholine and L-tyrosine.
The aim of this study was to evaluate the regulatory function of ZGJTYS on human gut microbiota and explore the effect of ZGJTYS on the intestinal flora response to L-α-phosphatidylcholine and L-tyrosine.
ZGJTYS was prescribed from the First Affiliated Hospital of Hunan University of Chinese Medicine. High-throughput sequencing of bacterial 16S RNA genes and fungal internal transcribed spacer (ITS) sequences was used for intestinal flora analysis. An gut microbiota simulation model was used to investigate the effect of ZGJTYS on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine. Ultra-high-performance liquid chromatography and mass spectrometry were used for non-targeted metabolomics analysis.
Compared to the control group, the microbial diversity of DKD was significantly reduced by ZGJTYS treatment; three bacterial genera, including , were significantly higher; eight bacterial genera, including , and the linoleic acid content were significantly lower. A receiver operating characteristic curve analysis using and showed an area under the curve greater than 0.75, indicating good predictive performance. ZGJTYS intervention restored some of the normal bacterial genera, such as and , which were regulated by L-α-phosphatidylcholine and L-tyrosine. Furthermore, ZGJTYS effectively restored several significantly different Kyoto Encyclopedia of Genes and Genomes metabolic pathways related to immunity and disease to normal, such as efferocytosis and tryptophan metabolism.
ZGJTYS was found to effectively restore the microbiota that were altered by L-α-phosphatidylcholine and L-tyrosine to normal, along with their metabolites. However, the mechanism by which ZGJTYS exerts its preventive and therapeutic effects on DKD through the gut microbiota still requires further study.
动物和细胞研究表明，左归降糖益肾汤（ZGJTYS）对糖尿病肾病（DKD）的治疗具有良好效果。我们之前的临床研究也表明，ZGJTYS预防DKD的方式与贝那普利相似。然而，ZGJTYS与人类肠道微生物群之间的相互作用需要进一步研究，特别是其对肠道菌群对可能增加DKD风险的食物成分（如L-α-磷脂酰胆碱和L-酪氨酸）反应的干扰。
本研究旨在评估ZGJTYS对人类肠道微生物群的调节功能，并探讨ZGJTYS对肠道菌群对L-α-磷脂酰胆碱和L-酪氨酸反应的影响。
ZGJTYS由湖南中医药大学第一附属医院提供。使用细菌16S RNA基因和真菌内转录间隔区（ITS）序列的高通量测序进行肠道菌群分析。使用肠道微生物群模拟模型研究ZGJTYS对肠道菌群对L-α-磷脂酰胆碱和L-酪氨酸反应的影响。采用超高效液相色谱和质谱进行非靶向代谢组学分析。
与对照组相比，ZGJTYS治疗显著降低了DKD的微生物多样性；包括 在内的三个细菌属显著升高；包括 在内的八个细菌属和亚油酸含量显著降低。使用 和 进行的受试者工作特征曲线分析显示曲线下面积大于0.75，表明预测性能良好。ZGJTYS干预恢复了一些由L-α-磷脂酰胆碱和L-酪氨酸调节的正常细菌属，如 和 。此外，ZGJTYS有效地将与免疫和疾病相关的几个显著不同的京都基因与基因组百科全书代谢途径恢复到正常水平，如胞葬作用和色氨酸代谢。
发现ZGJTYS有效地将被L-α-磷脂酰胆碱和L-酪氨酸改变的微生物群及其代谢产物恢复到正常水平。然而，ZGJTYS通过肠道微生物群对DKD发挥预防和治疗作用的机制仍需进一步研究。
Zotero 插件
